SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
IGC

IGC Pharma, Inc. (IGC)

NYSE: IGC · USD
Healthcare · Biotechnology
$0.18-$0.01 (-5.45%)
 
Market cap
$21.5M
Insider Score
Analyst consensus
Market Cap$21.47M-44.2%
Revenue (ttm)$1.11M
Net Income-$6.45M
EPS-$0.07
Shares Out116.69M
PE Ration/a
Forward PE-2.30
Dividendn/a
Ex-Dividend Daten/a
Volume443,432
Open$0.19
Previous Close$0.19
Day's Range$0.18 - $0.19
52-Week Range$0.08 - $0.36
Beta0.55
Analystsnone
Price Target$6.00(+3160.87%)
Earnings Daten/a
-7.50% (1D)
No price history available.

About IGC

IGC Pharma, Inc., a clinical stage pharmaceutical company, develops novel therapeutic candidates for neuropsychiatric and neurodegenerative disorders, with a primary focus on Alzheimer's disease in the United States and Colombia. The company's lead product is IGC-AD1 that is in Phase II clinical trial for the treatment of agitation in dementia due to Alzheimer's. Its pre-clinical stage product candidate includes TGR-63 and IGC-M3 to treat Alzheimer's disease. In addition, the company develops MINT-AD, an AI-driven assistant for healthcare providers. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023. IGC Pharma, Inc. was incorporated in 2005 and is headquartered in Potomac, Maryland.

Address
10224 Falls Road, Potomac, MD, 20854, United States
Market Cap
21 million
Employees
70
Industrial Classification
Biotechnology

Analyst consensus

Moderate Buy
1 Buy0 Hold0 Sell

1 firm rating IGC in the last 3 months, one vote each. Issuer-paid research is not counted.

1 Day
-3.16%
5 Days
+2.22%
1 Month
-23.33%
6 Months
-36.55%
1 Year
-44.24%

$IGC stock is featured in our Insider Trades datasets.

→ All Stock Lists

Recently reported changes in IGC holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by IGC's directors and management

Net Shares Purchased by Insiders−1−102025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

IGC Estimated quarterly lobbying spending

Source: U.S. Senate LDA

IGC Revenue by Segment or Geography

IGC's latest filing doesn't break out revenue by segment.

As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)

U.S. Patents

New IGC patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to IGC from public contracts

Source: USAspending.gov

Bull Case vs Bear Case

AI-generated from IGC’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
No data yet
—
Analyst Ratings
62% of score
60
News & Sentiment
38% of score
72

News check: IGC Pharma achieved patent protection across key markets for Alzheimer's drug candidate approaching Phase 2 readout, signaling meaningful clinical progress.

Recent Insider Activity

Buys
0
Sells
0
Buy Value
$0
Distinct Buyers
0

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.

ETFs that hold this stock

PSILAdvisorShares Psychedelics ETF0.38%

Weight is the stock’s share of each fund’s holdings.